ACC.09 JUPITER

ACC.09 におけるPRIMA、STICH trial報告

それ以外の羅列

JUPITER trial: Rosuvastatin cuts venous thromboembolism risk by 43%
The lipid-lowering drug rosuvastatin nearly halves the risk of symptomatic venous thromboembolism in apparently healthy people, a new analysis of the JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial has found.



HORIZONS-AMI: Stent thrombosis predictors revealed
Predictors of early and late stent thrombosis after percutaneous coronary intervention for ST-elevation myocardial infarction vary, according to the latest findings from the HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in AMI) trial.

AGIR-2: No benefit of prehospital over cath lab tirofiban for primary PCI
Giving high-dose tirofiban to patients with ST-elevation myocardial infarction while they are en route to hospital for primary percutaneous coronary intervention resulted in no better outcomes than if high-dose tirofiban was given upon arrival at the cath lab.


PROTECT AF: WATCHMAN device might be effective alternative to warfarin for stroke prevention in atrial fibrillation
Results from the PROTECT AF trial suggest that the novel, implantable WATCHMAN device holds promise to replace warfarin for the treatment of patients with atrial fibrillation.

SYNTAX: CABG cost-effective for complex coronary lesions, PCI for less complex coronary anatomy
A quality-of-life and cost-effectiveness analysis of the 1-year SYNTAX trial results reveals that the choice of PCI or CABG depends on angiographic complexity.